Role of Serotonin in the Pathophysiology of the Irritable Bowel Syndrome

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2004 Apr 22

PMID 15100164

Citations 110

Authors

Michael D Crowell

Affiliations

Soon will be listed here.

Abstract

The irritable bowel syndrome (IBS) is a complex disorder that is associated with altered gastrointestinal motility, secretion, and sensation. Serotonin (5-HT) is an important neurotransmitter and paracrine signalling molecule in the gastrointestinal tract. 5-HT release from enterochromaffin (EC) cells initiates peristaltic, secretory, vasodilatory, vagal and nociceptive reflexes. The enteric nervous system (ENS) comprises a semiautonomous effector system that is connected to the central autonomic network. Parasympathetic and sympathetic nerves modulate the ENS via afferent and efferent communications. Ongoing, bidirectional brain-gut interactions involving 5-HT pathways occur that significantly influence the effector systems. Altered 5-HT signalling may lead to both intestinal and extraintestinal symptoms in IBS. 5-HT directly and indirectly affects intestinal motor and secretory function and abnormalities may lead to either constipation or diarrhea. 5-HT modulates sensation and perception of visceral stimulation at peripheral and central sites. Therapeutic agents targeting altered 5-HT signalling may provide new, effective treatments for patients with IBS.

Citing Articles

Anxiety and Depression in Children with Irritable Bowel Syndrome-A Narrative Review.

Pop D, Man S, Farcau D Diagnostics (Basel). 2025; 15(4).

PMID: 40002584 PMC: 11853794. DOI: 10.3390/diagnostics15040433.

The role of colonic microbiota amino acid metabolism in gut health regulation.

Chen Y, Fang J Cell Insight. 2025; 4(2):100227.

PMID: 39926315 PMC: 11803165. DOI: 10.1016/j.cellin.2025.100227.

Study on the effects of Massa Medicata Fermentata with different formulations on the intestinal microbiota and enzyme activities in mice with spleen deficiency constipation.

Liang X, Wan D, Li X, Peng Y, Chen L Front Cell Infect Microbiol. 2025; 14():1524327.

PMID: 39844840 PMC: 11753248. DOI: 10.3389/fcimb.2024.1524327.

Serotoninergic Mechanisms of Action in the Relaxant Properties of Saccharomyces boulardii CNCM I-745 on the Intestine.

Girard P, Verleye M, Castagne V Dig Dis Sci. 2024; 70(1):191-202.

PMID: 39661276 PMC: 11761163. DOI: 10.1007/s10620-024-08786-y.

Early-Life Stress Induced by Neonatal Maternal Separation Leads to Intestinal 5-HT Accumulation and Causes Intestinal Dysfunction.

Yang D, Bai R, Li C, Sun Y, Jing H, Wang Z J Inflamm Res. 2024; 17:8945-8964.

PMID: 39588137 PMC: 11586501. DOI: 10.2147/JIR.S488290.

References

Coffin B, Farmachidi J, Rueegg P, Bastie A, Bouhassira D . Tegaserod, a 5-HT4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects. Aliment Pharmacol Ther. 2003; 17(4):577-85. DOI: 10.1046/j.1365-2036.2003.01449.x. View

Grider J, Foxx-Orenstein A, Jin J . 5-Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine. Gastroenterology. 1998; 115(2):370-80. DOI: 10.1016/s0016-5085(98)70203-3. View

Steens J, van der Schaar P, Penning C, Brussee J, Masclee A . Compliance, tone and sensitivity of the rectum in different subtypes of irritable bowel syndrome. Neurogastroenterol Motil. 2002; 14(3):241-7. DOI: 10.1046/j.1365-2982.2002.00332.x. View

Stacher G . Cilansetron. Solvay. Curr Opin Investig Drugs. 2002; 2(10):1432-6. View

Hansen M . Neurohumoral control of gastrointestinal motility. Physiol Res. 2003; 52(1):1-30. View

Drossman D, Thompson W . The irritable bowel syndrome: review and a graduated multicomponent treatment approach. Ann Intern Med. 1992; 116(12 Pt 1):1009-16. DOI: 10.7326/0003-4819-116-12-1009. View

Cooke H . Neurotransmitters in neuronal reflexes regulating intestinal secretion. Ann N Y Acad Sci. 2001; 915:77-80. DOI: 10.1111/j.1749-6632.2000.tb05225.x. View

Spiller R . Effects of serotonin on intestinal secretion and motility. Curr Opin Gastroenterol. 2001; 17(2):99-103. DOI: 10.1097/00001574-200103000-00001. View

Farup P, Hovdenak N, Wetterhus S, Lange O, Hovde O, Trondstad R . The symptomatic effect of cisapride in patients with irritable bowel syndrome and constipation. Scand J Gastroenterol. 1998; 33(2):128-31. DOI: 10.1080/00365529850166833. View

10.

Grundy D . Towards a reduction of rectal pain?. Neurogastroenterol Motil. 2002; 14(3):217-9. DOI: 10.1046/j.1365-2982.2002.00333.x. View

11.

Chen J, Pan H, Rothman T, Wade P, Gershon M . Guinea pig 5-HT transporter: cloning, expression, distribution, and function in intestinal sensory reception. Am J Physiol. 1998; 275(3):G433-48. DOI: 10.1152/ajpgi.1998.275.3.G433. View

12.

Chen J, Li Z, Pan H, Murphy D, Tamir H, Koepsell H . Maintenance of serotonin in the intestinal mucosa and ganglia of mice that lack the high-affinity serotonin transporter: Abnormal intestinal motility and the expression of cation transporters. J Neurosci. 2001; 21(16):6348-61. PMC: 6763151. View

13.

Prior A, Maxton D, Whorwell P . Anorectal manometry in irritable bowel syndrome: differences between diarrhoea and constipation predominant subjects. Gut. 1990; 31(4):458-62. PMC: 1378424. DOI: 10.1136/gut.31.4.458. View

14.

Chey W . Tegaserod and other serotonergic agents: what is the evidence?. Rev Gastroenterol Disord. 2003; 3 Suppl 2:S35-40. View

15.

Beubler E, KOLLAR G, Saria A, Bukhave K, Rask-Madsen J . Involvement of 5-hydroxytryptamine, prostaglandin E2, and cyclic adenosine monophosphate in cholera toxin-induced fluid secretion in the small intestine of the rat in vivo. Gastroenterology. 1989; 96(2 Pt 1):368-76. DOI: 10.1016/0016-5085(89)91560-6. View

16.

Gullikson G, Loeffler R, Virina M . Relationship of serotonin-3 receptor antagonist activity to gastric emptying and motor-stimulating actions of prokinetic drugs in dogs. J Pharmacol Exp Ther. 1991; 258(1):103-10. View

17.

Milo R . Use of the peripheral dopamine antagonist, domperidone, in the management of gastro-intestinal symptoms in patients with irritable bowel syndrome. Curr Med Res Opin. 1980; 6(9):577-84. DOI: 10.1185/03007998009109491. View

18.

Spiller R, Jenkins D, Thornley J, Hebden J, Wright T, Skinner M . Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut. 2000; 47(6):804-11. PMC: 1728147. DOI: 10.1136/gut.47.6.804. View

19.

Talley N, Phillips S, Haddad A, Miller L, Twomey C, Zinsmeister A . GR 38032F (ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man. Dig Dis Sci. 1990; 35(4):477-80. DOI: 10.1007/BF01536922. View

20.

Muller-Lissner S, Koch G, Talley N, Drossman D, Rueegg P, Dunger-Baldauf C . Subject's Global Assessment of Relief: an appropriate method to assess the impact of treatment on irritable bowel syndrome-related symptoms in clinical trials. J Clin Epidemiol. 2003; 56(4):310-6. DOI: 10.1016/s0895-4356(03)00027-1. View